Shine-On Bio (Stock Code: 6926.TWO) has signed a licensing agreement worth over NT$200M with Singapore’s leading biopharma company ESCO Aster (EA), granting rights to its patented exosome-based small molecule drug-loading technology.
 
This collaboration combines:
 

• Exosome drug delivery innovation
• cGMP facilities & bioreactor expertise
• Accelerating exosome-loaded small molecule drugs across ASEAN and ANZ.

 
Highlights:
 

• NT$200M upfront + 5% royalties
• SOB100 IND approved, Phase I in Oct 2025
• Exosomes: higher efficacy, fewer side effects
• ESCO Aster to develop exosome-based oncology products
• 30% CAGR, multi-billion USD potential by 2030s

 
Chairman Chiu-Ching Huang emphasized: This agreement marks a new chapter in Taiwan’s exosome innovation, setting the stage for global collaborations and safer, more effective cancer treatments.
 
Read More, Learn More: https://news.gbimonthly.com/tw/invest/show.php?num=80261
 
Follow us for more news and Taiwan biotech ecosystem updates: https://www.linkedin.com/company/73826868